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Abstract
Background: The use of spirometry for early detection of chronic obstructive pulmonary disease (COPD) is
still an issue of debate, particularly because of a lack of convincing evidence that spirometry has an added positive
effect on smoking cessation. We hypothesise that early detection of COPD and confrontation with spirometry
for smoking cessation may be effective when applying an approach we have termed "confrontational counselling";
a patient-centred approach which involves specific communication skills and elements of cognitive therapy. An
important aspect is to confront the smoker with his/her airflow limitation during the counselling sessions. The
primary objective of this study is to test the efficacy of confrontational counselling in comparison to regular health
education and promotion for smoking cessation delivered by specialized respiratory nurses in current smokers
with previously undiagnosed mild to moderate airflow limitation.
Methods/Design: The study design is a randomized controlled trial comparing confrontational counselling
delivered by a respiratory nurse combined with nortriptyline for smoking cessation (experimental group), health
education and promotion delivered by a respiratory nurse combined with nortriptyline for smoking cessation
(control group 1), and "care as usual" delivered by the GP (control group 2). Early detection of smokers with mild
to moderate airflow limitation is achieved by means of a telephone interview in combination with spirometry. Due
to a comparable baseline risk of airflow limitation and motivation to quit smoking, and because of the
standardization of number, duration, and scheduling of counselling sessions between the experimental group and
control group 1, the study enables to assess the "net" effect of confrontational counselling. The study has been
ethically approved and registered.
Discussion: Ethical as well as methodological considerations of the study are discussed in this protocol. A
significant and relevant effect of confrontational counselling would provide an argument in favour of early
detection of current smokers with airflow limitation. Successful treatment of tobacco dependence in respiratory
patients requires repeated intensive interventions. The results of this study may also show that respiratory nurses
are able to deliver this treatment and that intensive smoking cessation counselling is more feasible.
Trial registration: Netherlands Trial Register (ISRCTN 64481813).
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Background
Chronic obstructive pulmonary disease (COPD) is a pre-
ventable and treatable disease which is characterized by
airflow limitation that is not fully reversible [1]. Spirome-
try is the gold standard for the diagnosis and assessment
of the disease [1]. COPD is currently the fifth leading
cause of death worldwide [2], and projections for 2020
indicate further increase in global mortality, placing
COPD on the third position of lethal diseases [3]. Ciga-
rette smoking is by far the most important risk factor for
COPD, and smoking cessation is the single most effective
way to reduce the risk of developing COPD and to affect
the outcome in patients at all stages of the disease [4,5].
Underdiagnosis of COPD is a worldwide problem [6].
Most patients present to their doctor for various other rea-
sons but often have respiratory symptoms, and in those
who do present with respiratory symptoms, COPD is not
always suspected nor diagnosed [7]. Because of the irre-
versible and progressive nature of the disease, early inter-
vention is important. However, the use of spirometry for
early detection of COPD is still an issue of debate [8-10].
The most important counterargument is that there is no
convincing evidence that spirometry has an added posi-
tive effect on smoking cessation [11-13].
Why use spirometry for smoking cessation?
In theory, spirometry might be useful as a motivational
tool for smoking cessation in smokers who are at risk of
developing (or have) COPD. While most smokers
acknowledge that smoking is dangerous, many trivialize
their own perceived risk of the disease, or deny or avoid
information about the dangers of smoking in order to
reduce cognitive dissonance [14-18]. One might therefore
expect that confronting smokers with an objectively (by
spirometry) identified negative consequence of smoking
(airflow limitation) positively affects the outcome of their
quit attempt. This idea was already proposed in the 1960's
by Peters and Ferris who argued that assessing the negative
effects of smoking on lung function "might serve as a lever
to influence the young adult to reduce his smoking hab-
its" [19]. Since then, various studies have been performed
to study the efficacy of spirometry for smoking cessation.
The results, however, are inconclusive as shown in a the
systematic review by Wilt et al. on spirometry as a motiva-
tional tool for smoking cessation [11,12]. Also, previous
studies have one or more important methodological lim-
itations such as unstandardized counselling intensity,
incomparable or uncontrolled use of pharmacological
aids for smoking cessation between experimental and
control group, and different (or unclear) baseline levels of
lung function and motivation to quit smoking. More well-
designed research is needed to assess the efficacy of
spirometry for smoking cessation.
Hypothesis and research questions
We hypothesise that early detection of COPD and con-
frontation with spirometry for smoking cessation may be
effective if the following approach we have termed "con-
frontational counselling" is applied [20]. Confronting
patients with COPD is not an isolated approach but
should be integrated into state-of-the-art smoking cessa-
tion treatment. Confrontational counselling should con-
sist of several counselling sessions on an individual, face-
to-face level, under supervision of a trained smoking ces-
sation specialist, and in combination with evidence-based
pharmacological treatment for smoking cessation.
Our primary research question is: what is the efficacy of
confrontational counselling in comparison to regular
health education and promotion for smoking cessation
delivered by specialized respiratory nurses in current
smokers with previously undiagnosed mild to moderate
airflow limitation (i.e. GOLD [1] stage 1 and 2 COPD)
with regard to prolonged abstinence from smoking during
a period of 12 months?
In this group of smokers with previously undiagnosed
mild to moderate airflow limitation we want to address
the following secondary research questions:
1. Which baseline characteristics are predictors of out-
come (i.e. 12-month prolonged abstinence from smok-
ing)?
2. What are the effects of early detection of airflow limita-
tion and smoking cessation on lung function, perceived
specific health-related complaints, quality of life, and
mental health after 12 months follow-up?
3. What is the cost-effectiveness and cost-utility of early
detection in combination with confrontational counsel-
ling delivered by respiratory nurses?
4. What are the effects of labelling of disease (COPD) on
self-efficacy, perceived health status, quality of life and
mental health?
5. What are the ethical considerations of early detection of
airflow limitation and subsequent confrontational coun-
selling for smoking cessation?
Methods/Design
Study design
In short, the design of this study is a randomized control-
led trial comparing confrontational counselling delivered
by a respiratory nurse (RN) combined with nortriptyline
for smoking cessation (experimental group), health edu-
cation and promotion delivered by a RN combined with
nortriptyline for smoking cessation (control group 1), andBMC Public Health 2007, 7:332 http://www.biomedcentral.com/1471-2458/7/332
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"care as usual" delivered by the GP (control group 2).
Early detection of smokers with mild to moderate airflow
limitation is achieved by means of a telephone interview
in combination with spirometry. For an overview of the
study design see figure 1.
The efficacy of smoking cessation interventions in clinical
studies depends on the characteristics of the study popu-
lation, the intensity of behavioural support, and the use of
pharmacological aids for smoking cessation [21]. In order
to isolate the effect of confrontational counselling on
smoking cessation, other factors that are associated with
the outcome must be standardized between the compari-
son groups. All participants of this trial have previously
undetected mild to moderate airflow limitation. Partici-
pants from both the experimental group and control
group 1 receive an equally intensive counselling (in terms
of number, duration, and scheduling of counselling visits)
and dosage of nortriptyline for smoking cessation.
Another reason for using an active control is that it would
not be ethically sound to withhold smokers with airflow
limitation from smoking cessation treatment.
Sample size calculation
The primary research question aims at a contrast in effi-
cacy between the experimental group (confrontational
counselling) and control group 1 (health education and
promotion). Therefore, the calculation of the sample size
is based on the identification of a difference in proportion
of prolonged abstinence after 12 months between these
two groups. We estimated the relevant difference in pro-
portion to be 15%: 35% quitters in the experimental
group versus 20% quitters in control group 1. When
putting the risk of a type I-error at 5% and the risk of a
type II-error at 20%, 136 participants per group are
needed at onset to detect a difference in proportions of
15%. Considering 10% lost to follow-up, 150 participants
per group are needed in the experimental group and con-
trol group 1 (136 × 0.9-1). We expect a larger difference
between the experimental group (35%) and control group
2 (8% [22]). Therefore, less participants are needed in
control group 2. We used a formula for the calculation of
sample sizes of unequal groups and set the ratio between
the experimental group and control group 2 at 3:1. This
resulted in a minimum of 32 participants in control group
2 (taking into account 10% lost to follow-up).
Preparation of the trial
In preparation of the trial, all GPs in Dutch and Belgian
Limburg (the area surrounding the city of Maastricht)
have been informed about the study. We have prepared an
office for the screening, counselling, and follow-up visits
of participants at Medical Centre Annadal, Maastricht. We
have built a relational database for the control of all study
events and the collection of data. This is very important
because of the complexity of the study.
Recruitment of participants
Subjects are recruited in the general population (through
advertisements in local newspapers, flyers, posters, and
mailings to households) and in primary care practices
(during consultations and through posters and personal-
ized mailings) in Dutch and Belgian Limburg. The text in
the advertisements, on flyers, and on posters explains that
Maastricht University is performing a study on smoking
cessation treatment in which individual counselling is
combined with medication for smoking cessation. Cur-
rent smokers aged 35 to 70 years, who are motivated to
quit smoking, are asked to contact us by telephone or by
e-mail. We also refer to a website with information about
this study. No information about the target condition we
are looking for (airflow limitation) is given to participants
during recruitment.
In- and exclusion criteria and process of eligibility 
screening
Eligibility is screened in two steps; during an initial tele-
phone interview followed by spirometry. The following
inclusion criteria are checked during the telephone inter-
view: smoking history of 10 or more pack years; being
motivated to stop smoking; being competent to read and
speak Dutch; and reporting a respiratory symptom,
defined as an affirmative answer to at least one of the fol-
lowing three questions: "Do you cough regularly?", "Do
you cough up phlegm (sputum) when you don't have a
cold?" or "Have you been shorter of breath lately?". Exclu-
sion criteria are: evidence of a prior respiratory diagnosis,
defined by an affirmative answer to the question "Do you
have COPD, chronic bronchitis, asthma or asthmatic
bronchitis?". Participants are also not allowed to have
undergone a lung function test (spirometry) during the
preceding 12 months. One or more contraindications for
using the smoking cessation medication (nortriptyline)
are also reasons for exclusion, among others the current
use of anti-depressants. Nortriptyline is a tricyclic anti-
depressant which should not be used for smoking cessa-
tion in conjunction with another anti-depressant. After
the end of the telephone interview, an appointment for
spirometry at Medical Centre Annadal is scheduled. Sub-
jects are eligible for participation who have airflow limita-
tion defined as post-bd. FEV1/FVC < 70% in combination
with post-bd. FEV1≥ 50% of predicted value; i.e. mild
(GOLD 1) or moderate (GOLD 2) airflow limitation,
according to the international GOLD guideline [1]. The
results of spirometry are not discussed during or directly
after spirometry.
Subjects with severe airflow limitation (post-bd. FEV1/
FVC < 70% in combination with post-bd. FEV1 < 50% ofBMC Public Health 2007, 7:332 http://www.biomedcentral.com/1471-2458/7/332
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Design Figure 1
Design. FC = face-to-face counselling session; TC = telephone counselling session; TQD = target quit date; RN = respiratory 
nurse; GP = general practitioner.
Experimental group
individual counselling 
by RN, 
confrontation  
with spirometry,  
+ nortriptyline 
FC1: day 1 
FC2: day 8 
TQD (TC): day 14 
FC3: day 15 
Control group 1
individual counselling 
by RN, 
no confrontation  
with spirometry,  
+ nortriptyline 
FC1: day 1 
FC2: day 8 
TQD (TC): day 14 
FC3: day 15 
Control group 2
referral to GP for 
 “care as usual”, 
no confrontation  
with spirometry, 
pharmacotherapy ? 
 TQD estimated  
Block-randomization per 7 participants 
Unequal group allocation 3 : 3 : 1 
Telephone screening
Baseline spirometry 
Participant information letter 
Informed consent 
Baseline questionnaires 
Follow-up visit 1: day 50 
(5 weeks after TQD) 
questionnaires, cost-diary,  
urine cotinine 
Follow-up visit 2: day 197 
(6 months after TQD) 
questionnaires, cost-diary,  
urine cotinine 
Follow-up visit 3: day 379 
(12 months after TQD) 
questionnaires, cost-diary,  
urine cotinine, 
spirometry, exit interview BMC Public Health 2007, 7:332 http://www.biomedcentral.com/1471-2458/7/332
Page 5 of 13
(page number not for citation purposes)
predicted value) are excluded from participation and
advised to contact their GP or a lung physician for further
evaluation. Subjects without airflow obstruction (post-bd.
FEV1/FVC ≥ 70%) are also excluded. These smokers are
told that despite their normal lung function, they still are
at risk of getting other smoking related diseases which are
not measured by spirometry, such as cancer or cardiovas-
cular disease. They are strongly recommended to give up
smoking. Both groups of excluded smokers get the advice
to stop smoking and receive a box with information mate-
rial about all existing therapies for smoking cessation
from the Dutch foundation for a smoke free future (STIV-
ORO).
Spirometry
Spirometry is performed by two qualified research assist-
ants under permanent supervision of a pulmonologist
(GW) according to the criteria of the American Thoracic
Society (ATS)/European Respiratory Society (ERS) task
force for standardization of lung function testing [23,24]
using a Vitalograph® 2120 (Vitalograph Ltd, Buckingham,
England). After a minimum of three acceptable and repro-
ducible FVC manoeuvres, a bronchodilator (500 μg terb-
utaline) is administered to the subject in preparation for
the reversibility test. After 15 minutes, another series of
three FVC manoeuvres is performed. All spirometric test
results are independently validated by a pulmonologist
(GW) and by a specialised lung function laboratory assist-
ant who was not involved in the trial. In case of initial dis-
agreement, consensus is obtained during re-examination.
Informed consent procedure
Written information about the study is sent to the candi-
date participant after the telephone interview, along with
the informed consent form. The candidate has at least one
week time for reflection before spirometry and can contact
the researcher or the research assistant (RA) for further
information at any time. The informed consent form is
signed by the participant in presence of the RA during the
visit for baseline spirometry.
The participant information letter gives information
about the existence of two intervention groups only. It
says that in one group participants receive "care as usual"
by their own GP (this is control group 2) and in the other
group participants receive treatment from a trained RN.
The latter group is in fact a combination of the experimen-
tal group (confrontational counselling by RN + nortriptyl-
ine) and control group 1 (health education and
promotion by RN + nortriptyline). These two groups are
identical with regard to the number and duration of coun-
selling sessions and the use of nortriptyline, but differ
only concerning the content and style of the behavioural
support: confrontational counselling versus health educa-
tion and promotion. Just this difference in content must
not explicitly be mentioned in the participant informa-
tion letter in order to safeguard the internal validity of the
study. We would jeopardize the idea behind early detec-
tion of patients with airflow obstruction by means of
spirometry if we would speak about "confrontational
counselling" or mention the target condition (airflow lim-
itation). Participants must not know that we use results
from spirometry as part of one intervention. The design
we use is adapted from Zelen's design [25,26] which may
be particularly useful when evaluating the full unbiased
impact of screening interventions [27].
At the end of the study, after the 12-month follow-up visit,
all participants will indeed be fully informed about the
real nature of the study. All participants and their corre-
sponding GPs will be informed about the result of the
spirometry. If a GP needs the results of spirometry for the
regular care of his/her patient before the end of the study,
the required information will be provided. This procedure
is approved by the medical ethics committee of Maastricht
University and Maastricht University Hospital.
Randomization and planning procedure
All eligible subjects with previously undetected mild to
moderate airflow limitation are contacted by telephone a
few days after baseline spirometry to be randomised to
one of the three intervention groups (apart from those
candidates who changed their mind and who are no
longer willing to participate in the study). Also at this
moment, the results of spirometry are not discussed. The
database of the trial incorporates a randomization system
of seven participants per block, allowing an unequal
group allocation of 3 : 3 : 1; experimental group : control
group 1 : control group 2. When eligible subjects are con-
tacted by telephone, the RA randomises the subject by
pressing a button on the computer screen. The database
then randomly allocates the subject. Neither the primary
researcher nor any other person involved in the study can
predict or influence which treatment group the next par-
ticipant will be allocated to.
After randomization, all treatment and follow-up visits
are planned for the whole study period. A schedule with
all visits is sent to the participant. At the same time, the GP
of each participant is sent a letter informing the GP that
the participant is taking part in the study.
Experimental group and control group 1: L-MIS as the 
common basis of counselling
Participants from both the experimental group and con-
trol group 1 receive counselling delivered by a RN com-
bined with nortriptyline for smoking cessation. The
common basis for the counselling is the so-called "L-MIS"
protocol for the treatment of nicotine and tobacco addic-BMC Public Health 2007, 7:332 http://www.biomedcentral.com/1471-2458/7/332
Page 6 of 13
(page number not for citation purposes)
tion which has been implemented among all RNs in the
Netherlands in recent years [28].
The number of counselling sessions, their duration and
scheduling is fixed in both the experimental group and
control group 1 (see also figure 1). The first face-to-face
counselling session (FC1; day 1, duration 40 minutes)
starts with getting acquainted with each other. The RN
tries to build up a relationship with the participant which
is based on trust. The participant's smoking characteristics
are defined by asking about smoking status, cigarettes
smoked per day, and readiness to quit. Nicotine addiction
is assessed by number of cigarettes per day and moment
of smoking the first cigarette after waking up in the morn-
ing. The motivation for quitting smoking is assessed and
increased by asking the readiness for quitting and reasons
for smoking and quitting. Also, the health risks of smok-
ing are discussed and the pros of quitting. The use of
nortriptyline for smoking cessation is discussed, including
mechanism, dosage, administration, and possible side
effects (for more information about the study medication
see paragraph "use of nortriptyline for smoking cessa-
tion"). The participant starts with the intake of the study
medication the same day.
At the beginning of the second face-to-face counselling
session (FC2; day 8, duration 40 minutes), the use of the
study medication is evaluated and possible side effects are
discussed. Barriers of quitting and the most important
problems with previous quit attempts are discussed. The
RN tries to increase the participant's self-efficacy towards
smoking cessation. The focus of the second session is to
prepare the participant for the target quite day (TQD). The
RN discusses with the participant how to deal with the
most important barriers of quitting smoking. The RN
anticipates problems with withdrawal, difficult moments,
and craving. The RN provides pointers for the TQD and
schedules the telephone counselling on that day.
On the TQD (day 14), the participant is counselled on the
telephone (TC; duration 5 – 15 minutes). The RN evalu-
ates the quit attempt, discusses difficult moments, and
gives advice for quitting and abstaining from smoking.
The third face-to-face counselling session is scheduled
directly after the TQD (FC3; day 15, duration 40 minutes)
and starts with an evaluation of the quit attempt and the
use of the study medication (including possible side
effects). The RN discusses with the participants what is
going well and what is problematic with this quit attempt.
The RN identifies difficult moments and strategies to deal
with theses situations in the future. Participants who did
not quit smoking yet or who already relapsed are asked
about their reasons and are encouraged to try again.
The fourth face-to-face counselling session (FC4; day 22,
duration 40 minutes) basically resembles the third ses-
sion; the RN evaluates the quit attempt and the use of the
study medication. As this is the last counselling session,
the focus lies on preparing the participant for continua-
tion of the quit attempt during the follow-up period. The
participant is asked to continue with the intake of
nortriptyline according to the protocol. At the end of the
session, the RN asks the participant's feedback on the per-
ceived effectiveness of the behavioural support and the
study medication.
All RNs have had initial training in the use of the L-MIS
method and are experienced in the treatment of nicotine
addiction. All RNs are trained to use a tailored version of
the L-MIS protocol which is specifically designed for this
trial. The compliance of RNs with the treatment of partic-
ipants is stimulated by the use of a protocolized treatment
manual, including intervention registration forms provid-
ing information per session about all the aspects of smok-
ing cessation counselling to be addressed. The RNs are
trained to fill out these intervention forms during each
counselling session.
Discriminative component in the experimental group: 
confrontational counselling
The number of counselling sessions, the duration, and the
scheduling are identical in the experimental group and
control group 1. However, specific aspects of "confronta-
tional counselling" are added to the L-MIS in the experi-
mental group which discriminate the treatment from the
treatment in control group 1. These aspects derive from
the principles of "confrontational counselling" which we
have described in more detail elsewhere [29]. Confronting
patients with COPD is not an isolated approach but
should be integrated into state-of-the-art smoking cessa-
tion treatment. Confrontational counselling should con-
sist of several counselling sessions on an individual, face-
to-face level, under supervision of a trained smoking ces-
sation specialist, and in combination with evidence-based
pharmacological treatment for smoking cessation.
A key element of confrontational counselling is to con-
front the participant with his/her airflow limitation dur-
ing the first counselling session (FC1). The RN discusses
the results of the participant's individual baseline spirom-
etry and explains the manifestations of COPD; COPD is a
slowly progressive, irreversible but treatable disease. Most
importantly in this respect is to make the participant
understand that his/her cigarette smoking is the primary
cause of the disease. The negative effect of smoking on the
lungs is illustrated by showing and comparing images of a
normal lung and a "smoker's lung". The participant is
asked to recognize common symptoms, functional limita-
tions, and participation problems associated with COPD.BMC Public Health 2007, 7:332 http://www.biomedcentral.com/1471-2458/7/332
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The natural history of COPD is discussed and illustrated
using the so-called "Fletcher curve" (see also figure 2)
[30]. Confronting patients with a serious disease that has
a bad prognosis arouses fear. Fear arousal is not a goal in
itself and it is not likely to automatically lead to the
desired action (smoking cessation). Therefore, when dis-
cussing the results of spirometry, the RN tries to make the
participant understand that there is an effective and feasi-
ble therapy for the disease: smoking cessation. Because
airflow limitation has been detected early in the partici-
pant, early treatment is possible to avoid further damage.
Smoking cessation is the only therapy to reduce the pro-
gression of the disease resulting in prolonged life expect-
ancy and improved quality of life. The motivation of the
participant to stop smoking in combination with the
behavioural counselling offered by the RN and the smok-
ing cessation medication (nortriptyline) increases the
chance of the participant to quit smoking and to subse-
quently improve health. At the end of the session, the par-
ticipant receives a folder with background information on
COPD which is developed by the Dutch College of Gen-
eral Practitioners (NHG). In contrast to the experimental
group, participants from control group 1 are not being
confronted with the detected airflow limitation. The RN
from control group 1 is instructed not to discuss the result
of spirometry at any time, but to treat the participant as a
"healthy smoker".
The information about airflow limitation and COPD dur-
ing the first counselling session probably has impact on
the participant. At the beginning of the second counsel-
ling session (FC2), the RN asks the participant to reflect
on this information. The RN assesses whether the partici-
pant has processed the information correctly and provides
feedback on the thoughts, feelings, and beliefs the partic-
ipant reports. Again, the positive effect of smoking cessa-
tion on the history of lung function is stressed and
illustrated using the Fletcher curve. This is repeated during
later counselling sessions if necessary.
Confrontational counselling comprises more than merely
confronting the participant with his/her results from
spirometry. It is a patient-centred approach which
involves specific communication skills and elements of
cognitive therapy. An important condition is a relation-
ship (also known as alliance) between RN and participant
in which both roles are equivalent (rather than an expert-
recipient relationship). The RN respects the participant's
freedom of choice regarding his/her own smoking behav-
iour. The RN stimulates the participant to reflect on his/
her smoking behaviour by carefully listening to the partic-
ipant's story, using open ended questions, paraphrases,
and reflections. Confrontational counselling aims to
identify certain cognitions about smoking such as health
concerns, risk perception and self-exempting beliefs. The
RN tries to challenge irrational beliefs about smoking by
raising the smokers consciousness about these beliefs,
testing their reality, and by exploring the relationship
between beliefs and behaviour. An example for a typical
self-exempting belief of a smoker would be: "Smoking is
possibly not very harmful because many smokers live
long. My grandfather is 85 and he smoked all his life". The
RN will try to challenge this belief for instance by conduc-
tion an objective risk assessment, or by exploring biases in
the belief itself.
At the end of the first, second, and third counselling ses-
sion, the RN hands out a smoking cessation diary to the
participant. Homework is an essential element in cogni-
tive therapy, and self-monitoring diaries are used as extra
input for the counselling sessions. In the first diary (eval-
uated during FC2), participants have to record their smok-
ing behaviour; they have to count the number of cigarettes
smoked and have to describe one situation in which they
experience great desire to smoke. In the second diary, par-
ticipants have to record their thoughts when smoking.
Again they have to count the number of cigarettes and
have to describe one situation, but also what was on their
mind directly before and after lighting up. In the third
diary (evaluated during FC3), participants have to
describe both behaviour and thoughts in situation when
they have great desire to smoke.
To ensure the building of an alliance between RN and par-
ticipant, it is important the participant is counselled by
one and the same pulmonary nurse during the whole
intervention period to prevent contamination between
the groups. Consequently, each treatment group has its
own RNs. All RNs have had initial training in the use of
the L-MIS method and are experienced in the treatment of
nicotine addiction. Additionally, RNs from the interven-
"Fletcher curve" Figure 2
"Fletcher curve". Adapted from Fletcher & Peto (1977): 
The natural history of chronic airflow obstruction [30].
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tion group will receive a four-hour group training in con-
frontational counselling. The group training is lead by a
cognitive therapist (MJH) who acts as supervisor through-
out the study, and incorporates practical training with a
simulation patient. Supervision meetings between RNs
and the supervisor will be planned every 6 weeks during
the whole intervention period of the trial.
RNs from control group 1 do not receive an introductory
group training but receive feedback during regular evalua-
tion meetings between the RN and the principal investiga-
tor.
Control group 2: care as usual by GP
Participants from control group 2 are referred to their own
GP for smoking cessation treatment. They are asked to
make an appointment with their GP within the next ten
days. They are provided with a referral letter explaining to
the GP that the person is participating in a study on smok-
ing cessation. This letter does not give any information
about the results from spirometry and the fact that the
participant has airflow limitation. The GP is asked to pro-
vide the care he/she usually provides to patients who want
to quit smoking. In the Netherlands, primary "care as
usual" for smoking cessation involves the use of a proto-
col for low intensity health education and promotion, the
so-called "H-MIS" [22]. According to the protocol of the
H-MIS, the GP and/or the assistant takes the following
steps to assist the smoker during a quit attempt: determine
the smoking profile of the smoker, determine the motiva-
tion to stop smoking (and increase the motivation if nec-
essary), talk about the barriers of quitting smoking, set a
target quit date, discuss the use of smoking cessation aids,
and arrange follow-up. A semi-structured interview will be
used among participants from control group 2 during the
first follow-up visit (day 50) in order to assess whether
participants have consulted their GP and which treatment
for smoking cessation the GP has delivered.
Neither participants from control group 2 nor their GP
will be informed about the results from spirometry and
the detected airflow limitation. However, if a GP explicitly
requests the results from spirometry they will be provided
(see further paragraph "ethical considerations").
Use of nortriptyline for smoking cessation
Previous research has shown that the combination of
counselling and pharmacotherapy is more effective than
either alone [31-33] and international guidelines recom-
mend the use of pharmacotherapy in all patients trying to
make a quit attempt [21,34]. Participants from both the
experimental group and control group 1 receive an equal
dosage of nortriptyline (Nortrilen®) for smoking cessa-
tion. Nortriptyline is a tricyclic anti-depressant which has
been shown to be a cheap and effective alternative for the
anti-depressant bupropion (Zyban™) [31,35]. Participants
start taking nortriptyline on the day of the first counsel-
ling visit (FC1, day 1) in which they receive instructions
about the use of nortriptyline by the RN. A run-in period
of 10 days until the TQD is needed to achieve steady-state
blood levels of nortriptyline. From day 1 through day 3,
participants take one pill of 25 mg nortriptyline once a
day (preferably after dinner). From day 4 through day 7,
participants take 50 mg a day (given as two pills of 25
mg). As from day 8 through the end of the treatment
period (day 49), participants take 75 mg a day (given as
three pills of 25 mg). The RN monitors the correct use of
the medication and the occurrence of side-effects during
the intervention period. In case of unpleasant or severe
side-effects, the dosage will be reduced or the use of the
medication will be stopped. At the first follow-up visit
(day 50) the RA collects and counts the remaining pills.
Follow-up visits
Three follow-up visits for all participants are scheduled at
day 50 (approximately five weeks after the TQD), day 197
(approximately six months after the TQD), and day 379
(approximately twelve months after the TQD; see also fig-
ure 1). The TQD in participants from control group 2 is set
at 8 weeks after the day participants were randomized and
informed about group allocation. We estimated that this
would be sufficient time to schedule a consultation with
the GP and to prepare stopping smoking, and that the
time lag between day of randomization and TQD would
be about the same compared to the experimental group
and control group 1 (in the latter groups, we account for
a delay between day of randomization and start of treat-
ment). Participants receive a reminder letter including a
follow-up questionnaire and a cost-diary seven weeks
prior to all three visits. The RA calls every participant one
week prior to the visit to confirm the appointment. Minor
deviations from the scheduling of follow-up visits will be
allowed in order to retain as many participants in the
study as possible.
At every follow-up visit, participants hand in their ques-
tionnaire and cost-diary. The RA briefly discusses the quit
attempt. Urine is collected from every self-reported non-
smoker for the analysis of cotinine levels.
During the final follow-up visit, spirometry is repeated in
all participants. All spirometric outputs are carefully eval-
uated by a pulmonologist (GW) and reported to the par-
ticipant's GP by letter. All participants are asked to consult
their GP for information about their lung function and
further treatment.
Data collection
An overview of all measurements per visit is given in
table 1. The paper-and-pencil questionnaires are filled outBMC Public Health 2007, 7:332 http://www.biomedcentral.com/1471-2458/7/332
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at home by the participants and are handed in during the
visits. Completion of the questionnaires takes about 30
minutes. Data from the questionnaires will be double-
entered and checked by blinded assistants from the centre
for data and information management of Maastricht Uni-
versity (MEMIC).
Urine is collected from every self-reported non-smoker
during each follow-up visit to validate non-smoking. The
urine is kept in a 100 mL plastic cup with a screw cap and
temporarily stored in a refrigerator for a maximum of
seven days before delivery to the laboratory of the Depart-
ment of Health Risk Analysis and Toxicology (GRAT) of
Table 1: Overview of measurements per visit
Measurement Baseline visit Follow-up visit 1 (day 
50)
Follow-up visit 2 (day 
197)
Follow-up visit 3 (day 
379)
Demographic 
characteristics
•
Smoking:
Tobacco use and quit 
attempts [41]
￿￿￿￿
Fagerström Test for 
Nicotine Dependence 
(FTND) [42]
￿
Health perception: (self-
constructed questions)
h e a l t h  c o n c e r n s ￿￿￿￿
r i s k  p e r c e p t i o n ￿￿￿￿
s e l f - e x e m p t i n g  b e l i e f s ￿￿￿￿
Respiratory health 
complaints:
COPD diagnostic 
questionnaire [43, 44]
￿
Medical Research 
Council (MRC) 
dyspnoea scale [45, 46]
￿￿ ￿
Clinical COPD 
Questionnaire (CCQ) 
[47, 48]
￿￿￿￿
Health-related quality of 
life:
EuroQol (EQ-5D) [39, 
40]
￿￿￿￿
Short-form 36-item 
questionnaire (SF-36) 
[49, 50]
￿￿￿￿
Chronic Respiratory 
Questionnaire self-
reported (CRQ-SR) [51, 
52]
￿￿￿￿
Mental health:
Beck Depression 
Inventory (BDI) [53]
￿￿￿￿
Hospital Anxiety and 
Depression Scale 
(HADS) [54–56]
￿￿￿￿
Cost diary: measurement 
of direct en indirect 
medical and non-medical 
costs [38]
￿￿￿
Physical measurements:
Physical height and 
weight
￿￿￿￿
Post-bronchodilator 
spirometry
￿ ￿
Urine cotinine (only in 
self-reported quitters)
￿￿￿BMC Public Health 2007, 7:332 http://www.biomedcentral.com/1471-2458/7/332
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Maastricht University. The concentration of cotinine in
urine is measured by a highly specific radioimmunoassay
using monoclonal antibodies [36]. The reagents for the
assay are obtained from the Department of Biochemistry,
Brandeis University, Massachusetts, USA.
The analysts assessing the urine cotinine levels and all
assistants entering data from questionnaires are kept
blind to the group allocation of participants.
Data analysis
The primary outcome measure is prolonged abstinence
from smoking during a period of 12 months after the
TQD. Prolonged abstinence is defined as follows: absti-
nent from smoking at all three follow-up visits; at day 50
(approximately 5 weeks after the TQD), day 197 (after six
months), and day 379 (after 12 months). Participants are
allowed to miss the second follow-up visit (day 197) if
they have been abstinent from smoking at the first (day
50) and the last follow-up visit (day 379; interpolation).
A participant is defined as abstinent from smoking at a
follow-up visit if both of the following two conditions are
met:
1. urine cotinine level < 50 ng/mL [37] and
2. self-reported quitter, not having smoked a single ciga-
rette since stopped smoking.
All randomized subjects will be included in the analysis
and subjects not showing up at the follow-up visit or with
a missing value on one of the two above measures are
regarded as smokers (intention-to-treat analysis). Statisti-
cal difference in primary outcome will be analyses using
Chi-square tests.
The secondary research questions will be analysed as fol-
lows (see the last paragraph of the introduction for an
overview of all secondary research questions).
1. Baseline predictors of outcome will be analysed by
regressing the primary outcome measure (12-month pro-
longed abstinence) on candidate predictors measured at
baseline (such as age, sex, airflow limitation, previous
quit attempts, or nicotine dependence) in a multivariate
logistic regression model, controlling for treatment group.
2. The health effects of smoking cessation will be analysed
by regressing measures of lung function, perceived specific
health-related complaints, quality of life, and mental
health on abstinence at each follow-up visit using linear
regression models.
3. The cost-effectiveness and cost-utility of early detection
of airflow limitation in combination with smoking cessa-
tion will be analysed using data from the cost diaries [38].
Participants fill out these diaries during three periods of
six weeks each: during the intervention until the first fol-
low-up visit (day 50), during the period until the second
follow-up visit (day 197), and during the period until the
last follow-up visit (day 379). The economic evaluation is
based on direct medical costs (e.g. treatment costs,
spirometry), direct non-medical costs (e.g. reimburse-
ment of travelling expenses), and on indirect costs (e.g.
sickness absence), which are related to respiratory com-
plaints. Effects are measured in physical units (such as
number of successful quit attempts, FEV1) and Quality
Adjusted Life Years (QALY'S) are measured with the Euro-
Qol (EQ-5D) [39,40].
4. The effects of labelling of disease (COPD) will be ana-
lysed by mediation and moderation analyses using linear
and logistic regression models. The outcome variable in
these analyses is abstinence from smoking at the first fol-
low-up visit. Only data from the experimental group and
control group 1 will be used.
5. The ethical considerations of early detection of airflow
limitation will be analysed in a qualitative analysis using
data from the ethical exit interviews which are performed
in participants attending the last follow-up visit.
Ethical approval, review, and registration of the trial
Participants of this study are not fully informed about the
real purpose of the study at the beginning, which is to
detect and confront smokers with airflow limitation. Par-
ticipants from control group 1 and control group 2 are not
informed about their results of spirometry during the
intervention and follow-up period. This approach is nec-
essary to assess the additional effect of early detection of
and confrontation with airflow limitation above the
effects of individual counselling and medication use. As
already explained in the paragraph "informed consent",
all participants as well as their GPs will be fully informed
about the purpose of the study and the results of spirom-
etry after the last follow-up visit.
This procedure is approved by the medical ethics commit-
tee of Maastricht University and Maastricht University
Hospital. We believe that it is ethical to withhold informa-
tion about the results from spirometry to participants of
this study for at least two reasons. The first reason is that
the smokers participating in this trial would probably not
have been diagnosed with airflow limitation outside the
trial setting early due to the problem of underdiagnosis of
COPD in primary care. The second reason is that all smok-
ers from this trial receive the most effective therapy for air-
flow limitation from either the RN or their own GP, which
is smoking cessation treatment.BMC Public Health 2007, 7:332 http://www.biomedcentral.com/1471-2458/7/332
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Data from the ethical analysis, which is based on the inter-
views with participants during the last follow-up visit,
should provide information about the participants' view
on the ethical aspects of this trial.
The protocol of this study was extensively reviewed by the
funding organizations; the Dutch Asthma Foundation,
PICASSO for COPD, and Maastricht University Hospital.
The study is registered at the Netherlands Trial Register
(ISRCTN 64481813).
Time frame
The recruitment, inclusion, randomization, and treatment
of participants will start in 2005 and will continue until
2007. The follow-up of participants is planned until the
year 2008. All data will be continuously collected,
entered, and cleaned. The analysis of data regarding the
primary research question will not be initiated before the
completion of follow-up and data collection in the last
participants (during the course of the year 2008).
Discussion
We presented the protocol of a study assessing the efficacy
of confrontational counselling for smoking cessation in
current smokers with not earlier diagnosed mild to mod-
erate airflow limitation (i.e. GOLD stage 1 and 2 COPD).
The design of this study is a randomized controlled trial
comparing confrontational counselling delivered by a res-
piratory nurse (RN) combined with nortriptyline for
smoking cessation (experimental group), health educa-
tion and promotion delivered by a RN combined with
nortriptyline for smoking cessation (control group 1), and
"care as usual" delivered by the GP (control group 2). We
hypothesise that early detection of COPD and confronta-
tion with spirometry for smoking cessation is more effec-
tive than regular health education and promotion and
primary care as usual for smoking cessation.
In the design of this randomized controlled trial, the base-
line risk of all participants is the same; they all have previ-
ously undetected airflow limitation. Only participants
from the experimental group are confronted with their
disease. Participants from the two control groups are not
informed before the end of the trial. All other factors
which are known to be associated with abstinence from
smoking are standardised in both the experimental group
and control group 1: type of counsellor (RN), type of
counselling (face-to-face and by telephone), number and
duration of counselling sessions, and type (nortriptyline)
and dosage of smoking cessation medication. Therefore,
we are able to assess the "net" effect of confronting and
counselling smokers with COPD.
There are several critical success factors to be mentioned.
A large number of smokers will have to be screened in
order to obtain enough eligible participants. No smokers
with known airflow limitation are allowed to enter the
trial. Also, during the whole recruitment period, candidate
participants must not be informed about the real purpose
of the study at the beginning; to detect and confront
smokers with airflow limitation. This means that a large
number of smokers generally interested in quitting must
be recruited in order to filter out eligible smokers with air-
flow limitation.
We expect eligible smokers to have a strong preference to
be placed in one of the groups receiving counselling by a
RN in combination with smoking cessation medication,
because they may find this intervention more effective
than care as usual by their own GP. Therefore, we expect a
lower compliance in participants from control group 2
and differential lost to follow-up in this group. It should
be noted here that the intervention in control group 2 is
probably not care as usual for smoking cessation as it
appears in primary care. This is because smokers are more
or less "referred" from the study team to their GP and are
likely to ask for the same smoking cessation medication as
participants randomized to the other two groups
(nortriptyline).
Blinding of neither participants nor RNs is possible,
because we want to assess behavioural interventions. All
participants know what kind of counselling they receive,
as do the respiratory nurses who provide the counselling.
However, analysts assessing the cotinine levels and assist-
ants entering data from questionnaires are blinded for the
group allocation of participants.
The primary outcome, 12-month prolonged abstinence
from smoking, is estimated from abstinence measures at
three time points. This outcome is therefore no perfect
measure of continuous outcome, but it is a feasible esti-
mation, which is very usual in this field of research. Absti-
nence from smoking is the primary endpoint of this study,
but can be regarded as a surrogate for the expected long-
term positive effects of smoking cessation on health.
Conclusion
Early intervention in COPD is of paramount importance
because of the irreversible and progressive nature of the
disease. The use of spirometry for early detection of COPD
still is an issue of debate because of a lack of convincing
evidence that spirometry has an added positive effect on
smoking cessation. A significant and relevant effect of
confrontational counselling compared to regular health
education and promotion for smoking cessation would
provide an argument in favour of early detection of cur-
rent smokers with airflow limitation. Successful treatment
of tobacco dependence in respiratory patients requires
repeated intensive interventions. The results of this studyBMC Public Health 2007, 7:332 http://www.biomedcentral.com/1471-2458/7/332
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may show that RNs are able to deliver this treatment on
the and that intensive smoking cessation counselling is
more feasible for RNs than for physicians who often lack
time.
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